Showing results (471-480 of 494) with videos related to

Sort By:
Pageof 50
Cancers|January 11, 2024
Intragenic EGFR::EGFR.E1E8 Fusion (EGFRvIII) in 4331 Solid TumorsLan Zheng, Rajyalakshmi Luthra, Hector A Alvarez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2004
Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experienceAllen M Chen, Funda Meric-Bernstam, Kelly K Hunt, et al.
NPJ Precision Oncology|July 27, 2025
IL-6 predicts CDK4/6 inhibitor resistance, identifying STAT3 as a target in HR + /HER2-negative metastatic breast cancerNicole M Kettner, Tuyen N Bui, Juliana Navarro-Yepes, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 4, 2020
TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancerDi Ai, Jun Yao, Fei Yang, et al.
Cancer Research|June 28, 2014
Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancerYi-Hsin Hsu, Jun Yao, Li-Chuan Chan, et al.
Cancer Cell|November 22, 2016
Deubiquitination and Stabilization of PD-L1 by CSN5Seung-Oe Lim, Chia-Wei Li, Weiya Xia, et al.
Cell|August 19, 2007
IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathwayDung-Fang Lee, Hsu-Ping Kuo, Chun-Te Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2005
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancerAman U Buzdar, Nuhad K Ibrahim, Deborah Francis, et al.
Science Signaling|March 5, 2024
eEF1A2 promotes PTEN-GSK3β-SCF complex-dependent degradation of Aurora kinase A and is inactivated in breast cancerWarapen Treekitkarnmongkol, Luisa M Solis, Deivendran Sankaran, et al.
Plos Medicine|June 19, 2009
DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancerSteven T Lott, Nanyue Chen, Dawn S Chandler, et al.
Pageof 50